Neuroprotective Effects Exerted by a Combination of Selected Lactic Acid Bacteria in a Mouse Parkinsonism Model under

Daiana Pérez Visñuk1, Jean Guy LeBlanc2, Alejandra de Moreno de LeBlanc3

  • 1Centro de Referencia para Lactobacilos (CERELA-CONICET), Chacabuco 145, San Miguel de Tucumán,, T4000ILC, Tucumán, Argentina.

Neurochemical Research
|August 1, 2024
PubMed

Insights

This study shows a lactic acid bacteria (LAB) combination protects against Parkinson's disease (PD) neurodegeneration and improves motor function. The LAB mix, when combined with Levodopa-Benserazide, also helps restore gut health and does not interfere with PD treatment.

Area of Science:

  • Neuroscience
  • Microbiology
  • Immunology
  • Gastroenterology

Background:

  • Alterations in the microbiota-gut-brain axis are linked to intestinal and neuronal inflammation in Parkinson's disease (PD).
  • Existing PD treatments may benefit from adjunctive therapies targeting gut dysbiosis and neuroinflammation.

Purpose of the Study:

  • To investigate the neuroprotective mechanisms of a specific lactic acid bacteria (LAB) combination (MIX) in Parkinson's disease models.
  • To assess the efficacy of the LAB MIX as an adjuvant therapy alongside Levodopa-Benserazide treatment in a chronic parkinsonism model.

Main Methods:

  • In vitro: Neuronal cells exposed to MPTP neurotoxin and treated with bacterial extracts or conditioned media.
  • In vivo: Chronic MPTP-induced parkinsonism model in aged mice, evaluating motor skills, tyrosine hydroxylase (TH) expression, cytokine levels, fecal microbiota, and intestinal histology.
  • Assessment of LAB MIX interaction with Levodopa-Benserazide treatment.

Main Results:

  • The LAB MIX demonstrated neuroprotective effects, improving motor function and increasing TH+ cells in the brain.
  • LAB MIX administration modulated immune responses, reduced intestinal damage, and increased the villus length/crypt depth ratio.
  • Combined treatment with LAB MIX and Levodopa-Benserazide partially reversed intestinal dysbiosis, increasing Lactobacillaceae abundance, without interfering with Levodopa-Benserazide efficacy.

Conclusions:

  • The selected LAB combination exhibits antioxidant and immunomodulatory properties, contributing to neuroprotection in Parkinson's disease.
  • This LAB MIX shows potential as an adjuvant therapy for conventional PD treatments, improving both neurological and gastrointestinal symptoms.
  • Further evaluation of this LAB combination is warranted for its therapeutic potential in Parkinson's disease management.